Deep search
Search
Images
Copilot
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Eli Lilly Stock Slumps on Lowered Sales Forecast
Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The maker of weight-loss drugs Mounjaro and Zepbound said sales grew slower than expected in the fourth quarter.
pharmaphorum
42m
Lilly trims sales forecast on weaker obesity/diabetes growth
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
Rolling Out
21h
7 facts about this weight loss drugs that actually work
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...
6d
on MSN
What's in the 'Natural Mounjaro' Drink — and Should You Try It?
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
FiercePharma
14h
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Evening Standard on MSN
1d
Celebrities who’ve used Ozempic: Oprah Winfrey, James Corden, and more
While talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...
13d
Ozempic and Similar Drugs May Offer Health Benefits Beyond Weight Loss, Including Reduced Alcohol Cravings
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
20h
on MSN
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...
22h
on MSN
What is Mounjaro? Everything to know about NHS approved weight loss jab
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Eli Lilly and Company
Zepbound
weight loss
Ozempic
Glucagon-like peptide-1
Feedback